Results 121 to 130 of about 131,131 (300)

Biopsy-Proven Glomerulopathies in Romania: A 10-Year Nationwide Study

open access: yesLife
Glomerular diseases are a major cause of chronic kidney disease worldwide, yet epidemiological data from Eastern Europe, and Romania in particular, remain scarce.
Andreea Covic   +16 more
doaj   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres   +19 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Immune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis

open access: yesCell Proliferation, EarlyView.
Schematic diagram for the experimental design for adaptome immune repertoire analysing Dampness ZHENG across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis. ABSTRACT Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide.
Lipeng Tang   +21 more
wiley   +1 more source

A guide to laser microdissection‐based proteomics

open access: yesThe FEBS Journal, EarlyView.
This review takes researchers through the full laser microdissection proteomics workflow—from tissue preparation and image analysis to sample processing and mass spectrometry—offering practical solutions to common challenges at each step. Real‐world examples from across the field illustrate how the technology is being applied to disease tissue, making ...
Cheng Shen   +3 more
wiley   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden   +13 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

open access: yesImmunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude   +2 more
wiley   +1 more source

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han   +24 more
wiley   +1 more source

Understanding lupus nephritis: diagnosis, management, and treatment options

open access: yes, 2012
Chi Chiu MokDepartment of Medicine, Tuen Mun Hospital and Center for Assessment and Treatment of Rheumatic Diseases, Pok Oi Hospital, Hong Kong, ChinaAbstract: Systemic lupus erythematosus (SLE) predominantly affects women in their reproductive years ...
Mok CC
core  

Home - About - Disclaimer - Privacy